Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)

Efficacy and safety of anlotinib plus XELOX regimen as first-line therapy for mCRC: a single-arm, multicenter, phase II study (ALTER-C-001)

BackgroundAnlotinib showed encouraging anti-tumor activity in metastatic colorectal cancer (mCRC). This study was designed to assess the efficacy and safety of anlotinib plus XELOX as first-line therapy in mCRC patients.Materials and MethodsEligible patients aged ≥18 with mCRC were enrolled in this...

Full description

Bibliographic Details
Main Authors: Bo Song, Hai Hu, Li Zhang, Su-Juan Ye, Yong-Dong Jin, Chang-Ling Shang, Jun Zhang, Hao Sun, Ke Zhang, Bo Yi, Yun-Wei Han, Jin Yan
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-09-01
Series:Frontiers in Oncology
Subjects:
anlotinib
XELOX
metastatic colorectal cancer
efficacy
safety
first-line therapy
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1238553/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1238553/full

Similar Items